Arialief works by addressing the root cause behind symptoms of peripheral neuropathy and provides a comprehensive solution to ...

CLINICAL BENEFIT, INCLUDING CAFS AND SURVIVAL, IS GREATEST IN A SUBGROUP OF ALS PATIENTS THAT SERVES AS THE BASIS FOR THE RECENTLY AUTHORIZED PHASE 3 CONFIRMATORY STUDY ...

Louvain-la-Neuve, Belgique, 5 mai 2025 - Conformément à l'article 8:4 de l'arrêté royal du 29 avril 2019 portant exécution du Code belge des sociétés et associations, Ion Beam Applications SA ("IBA") ...

MiNK Therapeutics is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat ...

Louvain-la-Neuve, Belgium, May 5th, 2025 - In accordance with article 8:4 of the Royal Decree of 29 April 2019 executing the Belgian Code on Companies and Associations, Ion Beam Applications SA (“IBA” ...

NASHVILLE, Tenn., May 05, 2025 (GLOBE NEWSWIRE) -- The Healthcare Financial Management Association (HFMA) today presented Robert Olsen with the 2025 Frederick C. Morgan Individual Achievement Award, ...

The Company has granted the underwriter a 45-day option to purchase up to an additional 450,000 shares of its Class A Ordinary Shares at the Offering Price, representing 15% of the Class A Ordinary ...

Coloplast CEO Kristian Villumsen steps down from his CEO position as of today. The Board of Directors has asked Lars Rasmussen to step in as interim CEO.

The Company intends to use net proceeds from the Offering for expansion into new markets, R&D activities to expand its product portfolio, research and development activities, building brand awareness, ...

OSE Immunotherapeutics Announces >90% of Responders Maintained Symptomatic Remission Through Extension Period on Lusvertikimab Lusvertikimab well tolerated over the 24-week additional treatment period ...

Live webcast links for the fireside chats will be available at https://investors.werewolftx.com/news-and-events/events. Archived replays will be available for approximately 90 days following the ...

Registrational study in patients with tumor hyperinsulinism (HI) expected to commence mid-year. Designation underscores need for therapies to treat severe hypoglycemia in the onco ...